You can read more about the PIVOTAL study and our involvement here.
RSH Research and Development Team
International Clinical Trials Day – May 2017
The Research and Innovation Team at SaTH celebrated International Clinical Trials Day this month by getting involved in a campaign called ‘I Am Research’.
The idea of the campaign is for people to talk about great research, so on 19 May staff from the Clinical Trials Department promoted the excellent work being done at SaTH by delivering literature (and cake) and talking to patients and staff.
This year Clinical Trials Day took place on 20 May and is celebrated around the world to recognise the day that James Lind started what is considered to the first randomised clinical trial.
In May 1747 the HMS Salisbury of Britain’s Royal Navy fleet patrolled the English Channel at a time when scurvy is thought to have killed more British seamen than French and Spanish arms. Aboard the ship was surgeon mate James Lind, a pioneer of naval hygiene.
Acting on a hunch that scurvy was caused by putrefaction of the body that could be cured through the introduction of acids, Lind recruited 12 men for his test. Without stating what method of allocation he used, Lind allocated two men to each of six different daily treatments for a period of 14 days.
PRH Research and Development Team
The six treatments were:
- litres of cider
- 25 millilitres of elixir vitriol (dilute sulphuric acid)
- 18 millilitres of vinegar three times throughout the day before meals
- half a pint of sea water
- two oranges and one lemon continued for six days
- A medicinal paste made up of garlic, mustard seed, dried radish root and gum myrrh
Those allocated citrus fruits experienced “the most sudden and good visible effects,” according to Lind’s report.
The trials being done today are obviously much more complex than the test conducted by James Lind, but like Lind the team at SaTH are doing incredible work to benefit our patients.
Angela Loughlin, Research & Innovation Manager at SaTH, said: “We have recruited more than 2,000 patients to take part in clinical trials over the past financial year and have more than 120 different trials on-going at the moment in 16 different specialties. The majority of these are national and international trials but we also support SaTH employees and students from various Universities to turn their research ideas into projects.
“Clinical trials play a key role in helping the NHS improve healthcare and develop life-saving treatments. Here at SaTH we are doing some really interesting studies in areas such as Crohn’s Disease, Colitis and Post- Menopausal women.
“These are just some of the areas we are looking at and hopefully they will lead to ways we can improve patient care in the future, just like James Lind all those years ago.”
The Shrewsbury and Telford Hospital NHS Trust scoops 2 awards
The Shrewsbury and Telford Hospital NHS Trust were the recipients of two national awards recently for their involvement and recruitment into the National MS Registry study. The first award was for the quality of the data submitted by the research team to the study centre. The second award was for the quality of the linked participant consent by online secure linkage.
To date, a total of 578 patients have been consented by both Shrewsbury and Telford sites into this very important study. The aim of the study is to capture better high quality information about living with Multiple Sclerosis in the UK today.
By capturing and analysing such data, we will learn more about how to improve care and develop promising treatments. Also, the development of a comprehensive register will help to fuel campaigns for fair relevant policies and guidelines, as well as overall improved health care for our MS patients.
Clinical Trials Nominated in Clinical Research Network (CRN) Awards – September 2016
The Clinical Trials Team was recently nominated for an award at the CRN awards by the Sponsor of the Breast trial MAMMO-50. The Shrewsbury & Telford Hospital NHS Trust are the top recruiting site in the country for this trial, which aims to establish if patients aged 50 years or over can be identified who require less frequent mammographic surveillance, whilst investigating alternative methods of follow-up.